Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Asset Writedowns and Impairment (2021 - 2023)

Historic Asset Writedowns and Impairment for Oncology Institute (TOI) over the last 3 years, with Q4 2023 value amounting to $2.0 million.

  • Oncology Institute's Asset Writedowns and Impairment rose 258783.78% to $2.0 million in Q4 2023 from the same period last year, while for Sep 2024 it was $2.0 million, marking a year-over-year increase of 179428.57%. This contributed to the annual value of $2.0 million for FY2023, which is 32436.97% up from last year.
  • According to the latest figures from Q4 2023, Oncology Institute's Asset Writedowns and Impairment is $2.0 million, which was up 258783.78% from $33000.0 recorded in Q3 2023.
  • In the past 5 years, Oncology Institute's Asset Writedowns and Impairment ranged from a high of $2.0 million in Q4 2023 and a low of -$722000.0 during Q2 2021
  • For the 3-year period, Oncology Institute's Asset Writedowns and Impairment averaged around $189000.0, with its median value being $74000.0 (2022).
  • Data for Oncology Institute's Asset Writedowns and Impairment shows a peak YoY increase of 258783.78% (in 2023) and a maximum YoY decrease of 10285.71% (in 2023) over the last 5 years.
  • Oncology Institute's Asset Writedowns and Impairment (Quarter) stood at $250000.0 in 2021, then tumbled by 70.4% to $74000.0 in 2022, then surged by 2587.84% to $2.0 million in 2023.
  • Its Asset Writedowns and Impairment was $2.0 million in Q4 2023, compared to $33000.0 in Q3 2023 and -$3000.0 in Q2 2023.